Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage pharmaceutical company developing therapeutics for cardiopulmonary diseases, specifically Pulmonary Arterial Hypertension (PAH). The company's lead product candidate, IKT-001, is a prodrug of imatinib mesylate, designed to improve the gastrointestinal (GI) side effects commonly observed with oral imatinib mesylate. IKT-001 has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing that a 300 mg dose of IKT-001 is bioequivalent to a 230 mg dose of imatinib mesylate.
The company's Phase 3 study, named IMPROVE-PAH, is expected to be initiated in the first quarter of 2026. The study will be a two-part adaptive Phase 3 trial, with Part A being a double-blind, placebo-controlled study in 140 patients with a primary endpoint of Pulmonary Vascular Resistance (PVR) at Week 24. Part B will adopt an identical format to Part A, except the primary endpoint will be 6-minute walk distance at Week 24 in 346 patients.
IKT-001 emerged from the company's medicinal chemistry program aimed at developing improvements to drugs that inhibit Abelson Tyrosine Kinase and type III receptor tyrosine kinases. The company has discussions with the FDA regarding Orphan Drug Designation (ODD) for delivery of imatinib by IKT-001 for PAH and plans to apply for ODD once the required pre-clinical studies are complete. The company currently has global commercialization rights to IKT-001 and patent protection in the United States until 2033.
The company previously pursued risvodetinib (IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases targeting the treatment of Parkinson’s disease, but it has been discontinued and outlicensed this program.
Investing in IKT's common stock involves a high degree of risk, including the risks related to the success of its product candidates, clinical trials, regulatory approvals, and market acceptance. The company plans to use the net proceeds from the offering, if any, primarily for general corporate purposes, which may include clinical trials, product candidate development and manufacturing activities for IKT-001 and other product candidates, other research and development activities, acquisitions of new technologies or businesses, and the remainder for working capital, capital expenditures and other general corporate purposes.
